Bryan Irving has joined Amunix Pharmaceuticals as chief scientific officer, the same postion he held at Five Prime Therapeutics (NASDAQ: [[ticker:FPRX]]). Irving’s experience also includes posts at CytomX and Genentech. Mountain View, CA-based Amunix is developing protein-based therapies for cancer and other diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
